Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report

Saved in:

Bibliographic Details
Published in	Annals of oncology Vol. 31; no. 7; pp. 961 - 964
Main Authors	Michot, J.-M., Albiges, L., Chaput, N., Saada, V., Pommeret, F., Griscelli, F., Balleyguier, C., Besse, B., Marabelle, A., Netzer, F., Merad, M., Robert, C., Barlesi, F., Gachot, B., Stoclin, A.
Format	Journal Article
Language	English
Published	England Elsevier Ltd 01.07.2020 European Society for Medical Oncology. Published by Elsevier Ltd
Subjects	Adult Antibodies, Monoclonal, Humanized - therapeutic use Autoantibodies - therapeutic use Betacoronavirus Coronavirus Infections - complications Coronavirus Infections - diagnostic imaging Coronavirus Infections - drug therapy COVID-19 Humans Letter to the Editor Male Pandemics Pneumonia, Viral - complications Pneumonia, Viral - diagnostic imaging Pneumonia, Viral - drug therapy Receptors, Interleukin-6 - antagonists & inhibitors Respiratory Insufficiency - diagnostic imaging Respiratory Insufficiency - drug therapy Respiratory Insufficiency - etiology SARS-CoV-2 Treatment Outcome
Online Access	Get full text
ISSN	0923-7534 1569-8041 1569-8041
DOI	10.1016/j.annonc.2020.03.300

More Information
Bibliography:	ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Correspondence-3 content type line 23 ObjectType-Report-1 These authors equally contributed.
ISSN:	0923-7534 1569-8041 1569-8041
DOI:	10.1016/j.annonc.2020.03.300